Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Boundless Bio's annualized positive value of Interest Expense for the quarter that ended in Mar. 2026 was $0.00 Mil. Boundless Bio's average total debt for the quarter that ended in Mar. 2026 was $48.66 Mil. Therefore, Boundless Bio's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2026 was 0.00%.
Boundless Bio (NAS:BOLD) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Boundless Bio Effective Interest Rate on Debt % Related Terms
Boundless Bio Effective Interest Rate on Debt % Historical Data
* Premium members only.
The historical data trend for Boundless Bio's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boundless Bio Effective Interest Rate on Debt % Chart
BOLD vs INKT, FLNA, DWTX: Effective Interest Rate on Debt % Comparison
For the Biotechnology subindustry, Boundless Bio's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boundless Bio Effective Interest Rate on Debt % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Boundless Bio's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Boundless Bio's Effective Interest Rate on Debt % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data,
the Interest Expense data used here is four times the quarterly (Mar. 2026) interest expense data.
Effective Interest Rate on Debt % is displayed in the 30-year financial page.
What does a Effective Interest Rate on Debt % of 0.00% mean?
Boundless Bio (BOLD) has a Effective Interest Rate on Debt % of 0.00% as of Mar. 2026. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Boundless Bio and its competitors.
Is Boundless Bio's Effective Interest Rate on Debt % too high?
Boundless Bio's current Effective Interest Rate on Debt % is 0.00%. Overall, Boundless Bio has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Boundless Bio's Effective Interest Rate on Debt % compare to INKT and FLNA?
Boundless Bio's Effective Interest Rate on Debt % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Boundless Bio and its competitors. Boundless Bio's current Effective Interest Rate on Debt % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boundless Bio stock overvalued right now?
Boundless Bio (BOLD) has a current Effective Interest Rate on Debt % of 0.00%. The current Effective Interest Rate on Debt % is 0.00%. Boundless Bio's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Boundless Bio (BOLD), the current Effective Interest Rate on Debt % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
14GF Score
Get the complete analysis for BOLD
Effective Interest Rate on Debt % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOLD has been successfully added to your 
